Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta 1a - Synairgen

Next Previous
Drug Profile

Interferon beta 1a - Synairgen

Alternative Names: AZD 9412; inhaled interferon beta - Synairgen; SNG-001

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Southampton
  • Developer AIDS Clinical Trials Group; Synairgen
  • Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
  • Mechanism of Action Immunomodulators; Interferon beta-1a replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Chronic obstructive pulmonary disease
  • No development reported Influenza virus infections
  • Discontinued Asthma

Most Recent Events

  • 31 May 2025 Synairgen plans the phase II INVENT trial in Respiratory syncytial virus infections (Inhalation), in July 2025 (NCT06999603) (EudraCT2024-520375-27-00)
  • 15 Jan 2025 Synairgen plans a phase II trial for Chronic obstructive pulmonary disease in the coming months
  • 21 Sep 2023 Synairgen plans clinical trials for SNG 001 in H1 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top